70527-40-1

Basic information

• Product Name: N-(3,4-Dichloro-phenyl)-N-{(1R,2R)-2-[(2-dimethylamino-ethyl)-methyl-amino]-cyclopentyl}-propionamide
• CAS NO: 70527-40-1
• Molecular Weight: 386.365
• Mol File: 70527-40-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3,4-Dichloro-phenyl)-N-{(1R,2R)-2-[(2-dimethylamino-ethyl)-methyl-amino]-cyclopentyl}-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-Dichloro-phenyl)-N-{(1R,2R)-2-[(2-dimethylamino-ethyl)-methyl-amino]-cyclopentyl}-propionamide(70527-40-1)
• EPA Substance Registry System: N-(3,4-Dichloro-phenyl)-N-{(1R,2R)-2-[(2-dimethylamino-ethyl)-methyl-amino]-cyclopentyl}-propionamide(70527-40-1)

Safety Data

• Hazardous Substances Data: 70527-40-1(Hazardous Substances Data)

Upstream product

• 285-67-6 Cyclopentene oxide 
• 142-25-6 N,N',N'-trimethylenediamine 
• 67440-32-8 (1S,2S)-2-[(2-Dimethylamino-ethyl)-methyl-amino]-cyclopentanol 
• 123-62-6 propionic acid anhydride 
• 67629-76-9 (1S,2S)-N-(3,4-Dichloro-phenyl)-N'-(2-dimethylamino-ethyl)-N'-methyl-cyclopentane-1,2-diamine 
• 95-76-1 m,p-dichloroaniline 
• 79-03-8 propionyl chloride 

Relevant articles and documents

A new nontricyclic antidepressant agent. Synthesis and activity of N-[trans-2-(dimethylamino)cyclopentyl]-N-(3,4-dichlorphenyl)propanamide and related compounds

A series of new nontricyclic antidepressant compounds was synthesized. A representative of this class is shown. Five structural parameters were investigated: ring size, cis/trans stereochemistry, amide substitution, aromatic substitution, and amine substi

N-(2-Aminocyclopentyl)acylanilides and treating depression

N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula STR1 e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depresssant properties. Many of them are new. These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.